Is it beneficial to selectively boost high-risk tumor subvolumes? A comparison of selectively boosting high-risk tumor subvolumes versus homogeneous dose escalation of the entire tumor based on equivalent EUD plans

Acta Oncologica

Volumn 47, Issue 5, 2008, Pages 906-916

  Kim, Yusung ^a   Tomé, Wolfgang A ^b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER FUNCTION; CANCER CONTROL; CANCER RISK; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TUMOR VOLUME;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RELATIVE BIOLOGICAL EFFECTIVENESS; RISK FACTORS;

EID: 45849093738     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701843050     Document Type: Article

References (35)

1. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1274-6.
2. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000;18:3904-11.
3. Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, et al. Randomized trial comparing iridum implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005;23:1192-9.
4. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005;23:6132-8.
5. Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004;100:538-43.
6. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53: 1097-105.
7. Zelefsky MJ, Fuks Z, Leibel SA. Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol 2002;12:229-37.
8. Kim Y, Tomé WA. Risk-adaptive optimization: Selective boosting of high-risk tumor subvolumes. Int J Radiat Oncol Biol Phys 2006;66:1528-42.
9. De Meerleer G, Villeirs G, Bral S, Paelinck L, De Gersem W, Dekuyper P, et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotheraphy. Radiother Oncol 2005;75:325-33.
10. 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006;65:291-303.
11. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intraprostatic lesion to 90 Gy compared to seven field 3-dimentional radiotherapy. Int J Radiat Oncol Biol Phys 1999;44:921-9.
12. Xia P, Pickett B, Vigneault E, Verhey LJ, Roach M III. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 2001;51:244-54.
13. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005;6:112-7.
14. Tomé WA, Fowler JF. Selective boosting of tumor subvolumes. Int J Radiat Oncol Biol Phys 2000;48:593-9.
15. 18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol 2006;79:249-58.
16. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, et al. A novel approach to overcome hypoxic tumour resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171-82.
17. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
18. Brahme A. Optimized radiation therapy based on radiobiological objectives. Semin Radiat Oncol 1999;9:35-47.
19. Levegrün S, Jackson A, Zelefsky MJ, Venkatraman ES, Skwarchuk MW, Schlegel W, et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol 2002;63:11-26.
20. Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Borca VC, et al. Fitting late rectal bleeding data using different NTCP models: Results from an Italian multicentric study (AIROPROS0101). Radiother Oncol 2004;73:21-32.
21. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991;21:123-35.
22. Bentzen SM, Tucker SL. Quantifying the position and steepness of radiation dose-response curves. Int J Radiat Biol 1997;71:531-42.
23. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method. Int J Radiat Oncol Biol Phys 1989;16:1623-30.
24. Tucker SL, Dong L, Cheung R, Johnson J, Mohan R, Huang EH, et al. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys 2004;60: 1589-601.
25. Munro TR, Gilbert CW. The relation between tumour lethal doses and the radiosensitivity of tumour cells. Br J Radiol 1961;34:246-51.
26. Huang EH, Pollack A, Levy L, Starkschall G, Dong L, Rosen I, et al. Late rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002;54:1314-21.
27. Jackson A, Skwarchuk MW, Zelefsky MJ, Cowen DM, Venkatraman ES, Levegrün S, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer (II): Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 2001;49:685-98.
28. Fiorino C, Cozzarini C, Vavassori V, Sanguineti G, Bianchi C, Cattaneo GM, et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: Analysis of a large group of patients pooled from three institutions. Radiother Oncol 2002;64:1-12.
29. Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995;31:1257-80.
30. Thorwarth D, Eschmann S, Paulsen F, Alber M. Hypoxia dose painting by numbers: A planning study. Int J Radiat Oncol Biol Phys 2007;68:291-300.
31. Malinen E, Søvik Å, Hristov D, Bruland ØS, Olsen DR. Adapting radiotherapy to hypoxic tumours. Phys Med Biol 2006;51:4903-21.
32. Yang Y, Xing L. Towards biologically conformal radiation therapy (BCRT): Selective IMRT dose escalation under the guidance of spatial biology distribution. Med Phys 2005;32:1473-84.
33. Wang X, Mohan R, Jackson A, Leibel SA, Fuks Z, Ling CC. Optimization of intensity-modulated 3D conformal treatment plans based on biological indices. Radiother Oncol 1995;37:140-52.
34. Mohan R, Wang X, Jackson A, Bortfeld T, Boyer AL, Kutcher GJ, et al. The potential and limitations of the inverse radiotherapy technique. Radiother Oncol 1994;32:232-48.
35. Niemierko A. Reporting and analyzing dose distributions: A concept of equivalent uniform dose. Med Phys 1997;24:103-10.